Berkeley, United States
Valitor, Inc. is a biotechnology company founded in 2010 with a focus on developing advanced, protein-based drugs. Their core technology allows the modification of existing biological therapies to gain substantial control over their pharmacological properties. The company's mission is to create a new generation of biologic therapies that reduce the costs associated with effective disease treatment and enhance patients' quality of life by reducing the frequency of therapeutic administration. Valitor has initiated a pipeline of drug products targeting diseases that impose a significant financial burden on the nation's healthcare system.
The company is headquartered in the United States and most recently received a $28.00M Series B investment on 05 October 2022. The investors in this round included ExSight Ventures, Berkeley Catalyst Fund, First Spark Ventures, Morningside Venture Investments, and Pandect Bioventures. Valitor's focus on innovative biologic therapies and its vision for improving treatment outcomes while reducing costs could make it an attractive investment opportunity in the biotechnology sector.
Valitor is also actively seeking talent and is currently hiring. More details about career opportunities at Valitor can be found on their website: http://www.valitorbio.com/careers.html.
